Targeting protein-protein interactions (PPIs): Identifying PPI inhibitors for novel therapeutics

Dr. David Andrews, AstraZeneca, discusses the future of small-molecule drug discovery for PPIs

19 Apr 2021
Edward Carter
Publishing / Media

Editorial article

Dr. David Andrews, Director of Pre-Clinical Scientific Alliances, AstraZeneca

Proteins control a variety of intra- and extracellular biological processes and when sequenced or expressed and activated incorrectly can increase the likelihood of disease. Protein-protein interactions (PPIs) are fundamental in the stable running of cellular processes where they can alter the kinetic properties of enzymes, create new binding sites, inactivate proteins, and change the specificity of a protein. PPIs can be manipulated by small molecules that can change the outcome of a variety of different cellular processes. The inhibition of these cellular processes can prevent diseases, therefore, inhibiting PPIs is becoming increasingly attractive for novel therapeutics.

In this SelectScience® interview, we speak with Dr. David Andrews, Director of Pre-Clinical Scientific Alliances, AstraZeneca, to discuss the latest work of the Perturbation of Protein-Protein Interactions (PoPPI) program, a collaboration between the University of Leeds, University of Bristol, Northern Institute for Cancer Research, AstraZeneca and Domainex, to examine the impact of potential therapies for cancers and neurological diseases which target PPIs.

Why are protein-protein interactions an important set of targets in drug discovery?

DA: The revolution in gene sequencing has led to the identification of many proteins that are mutated, deleted, or amplified in disease. In many cases, the enzyme or receptor functionality of these new proteins is modulated by their interaction with other proteins. Additionally, we are now seeing the emergence of protein targets of interest that have no known function, in which case their scaffold or other PPI functions become highly pertinent.

How is PoPPI working to address the challenges of identifying small molecules to target PPIs?

DA: PoPPI is applying a wide range of techniques to help better understand small molecule-PPI interactions. Of the methods being explored, I have a keen interest in computational methods, biophysics, and chemical biology.

What are the latest findings from this work?

DA: We have developed a workflow that we term ‘query-guided PPI inhibitor discovery’. This is implemented through several stages that combine established computational tools and experimental validation. Initially, a query is built that incorporates the key secondary structural motif and hot residues from the PPI. A virtual library of small molecules is then shape-matched against the query, and promising compounds docked against the target protein. Candidate inhibitors are then subjected to experimental screening and hits are selected using conventional hit-to-lead methods. We’ve just published this work in the open-access RSC journal Chemical Science1.

How will this work impact the future of small molecule drug discovery for PPIs?

DA: We hope that establishing a workflow and toolkit will enable researchers to identify PPI inhibitor start points using AI and computational methods, rather than relying on ‘brute force’ high-throughput screening strategies.

How do you hope this work will ultimately aid the understanding of disease and impact patient care?

DA: There can be very few, if any, therapy areas that do not exemplify protein-protein interactions as targets. In our paper, we illustrated the workflow with one PPI each from the neuroscience and oncology fields of study1. In an unrelated, late-2020 publication, the first pan-coronavirus interactome was published illustrating the wide relevance of these targets to anti-infectives2.

Discover more advancements in the field of drug discovery in our Advances in Drug Discovery Special Feature>>

References

Celis S, Hobor F, James T, Bartlett GJ, Ibarra AA, Shoemark DK, Hegedus Z, Hetherington K, Woolfson DN, Sessions RB, Edwards TA, Andrews DM, Nelson A, Wilson, AJ. Query-guided protein–protein interaction inhibitor discovery. Chemical Science. 2021

Gordon DE, Hiatt J, Bouhaddou M, Rezelj VV, Ulferts S, Braberg H, Jureka AS, Obernier K, Guo JZ, Batra J, Kaake RM, Weckstein AR, Owens TW, Gupta M, Pourmal S, Titus EW, Cakir M, Soucheray M, McGregor M, Cakir Z, Jang G, O'Meara MJ, Tummino TA, Zhang Z, Foussard H, Rojc A, Zhou Y, Kuchenov D, Hüttenhain R, Xu J, Eckhardt M, Swaney DL, Fabius JM, Ummadi M, Tutuncuoglu B, Rathore U, Modak M, Haas P, Haas KM, Naing ZZC, Pulido EH, Shi Y, Barrio-Hernandez I, Memon D, Petsalaki E, Dunham A, Marrero MC, Burke D, Koh C, Vallet T, Silvas JA, Azumaya CM, Billesbølle C, Brilot AF, Campbell MG, Diallo A, Dickinson MS, Diwanji D, Herrera N, Hoppe N, Kratochvil HT, Liu Y, Merz GE, Moritz M, Nguyen HC, Nowotny C, Puchades C, Rizo AN, Schulze-Gahmen U, Smith AM, Sun M, Young ID, Zhao J, Asarnow D, Biel J, Bowen A, Braxton JR, Chen J, Chio CM, Chio US, Deshpande I, Doan L, Faust B, Flores S, Jin M, Kim K, Lam VL, Li F, Li J, Li YL, Li Y, Liu X, Lo M, Lopez KE, Melo AA, Moss FR 3rd, Nguyen P, Paulino J, Pawar KI, Peters JK, Pospiech TH Jr, Safari M, Sangwan S, Schaefer K, Thomas PV, Thwin AC, Trenker R, Tse E, Tsui TKM, Wang F, Whitis N, Yu Z, Zhang K, Zhang Y, Zhou F, Saltzberg D; QCRG Structural Biology Consortium, Hodder AJ, Shun-Shion AS, Williams DM, White KM, Rosales R, Kehrer T, Miorin L, Moreno E, Patel AH, Rihn S, Khalid MM, Vallejo-Gracia A, Fozouni P, Simoneau CR, Roth TL, Wu D, Karim MA, Ghoussaini M, Dunham I, Berardi F, Weigang S, Chazal M, Park J, Logue J, McGrath M, Weston S, Haupt R, Hastie CJ, Elliott M, Brown F, Burness KA, Reid E, Dorward M, Johnson C, Wilkinson SG, Geyer A, Giesel DM, Baillie C, Raggett S, Leech H, Toth R, Goodman N, Keough KC, Lind AL; Zoonomia Consortium, Klesh RJ, Hemphill KR, Carlson-Stevermer J, Oki J, Holden K, Maures T, Pollard KS, Sali A, Agard DA, Cheng Y, Fraser JS, Frost A, Jura N, Kortemme T, Manglik A, Southworth DR, Stroud RM, Alessi DR, Davies P, Frieman MB, Ideker T, Abate C, Jouvenet N, Kochs G, Shoichet B, Ott M, Palmarini M, Shokat KM, García-Sastre A, Rassen JA, Grosse R, Rosenberg OS, Verba KA, Basler CF, Vignuzzi M, Peden AA, Beltrao P, Krogan NJ. Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms. Science. 2020

Links

Tags

Cell Lines Stem Cells and Primary CellsPrimary cell cultures, established cell lines and stem cells are vital for <i>in vitro</i> and <i>ex vivo</i> experimentation. High-quality cells, optimized for your applications, alongside optimized cell substrates, growth medium and supplements, are critical for experimental success. Explore a range of cells suitable for your applications, including isogenic cell lines, competent cells, induced pluripotent stem cell (iPSC)-derived cell lines, fungal/bacterial/mammalian cell lines, stem cells and cancer cell lines. Find the best cells for your research in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.HematologyIn Haematology / Hematology, complete blood cell counts (or full blood counts) are obtained using automated blood count analyzers to enumerate blood cell types.  Hematology also encompasses haemostasis and coagulation, thrombophilia and hemophilia, plasma viscosity and ESR analysis, hemoglobinopathies, cell morphology and haematinic measurement.ImmunologyImmunological techniques measure and characterize immune responses. Immunology kits and analysis systems often use techniques such as ELISA, radioimmunoassay (RIA) and immunodiffusion assays, Immunohistochemistry, and flow cytometry. Immunologists use equipment such as flow Cytometers, plate readers, plate washers and fluorescent microscopes.Cellular PathologyCellular Pathology deals with the microscopic analysis of tissue samples and cells. Sample preparation and processing includes fixation, staining, sectioning and slide mounting, using equipment such microtomes and cryostats. In choosing immunohistochemistry and immunocytochemistry kits, consider chromogens, staining method, antibodies, microscopes and imaging.Protein QuantificationThe detection and quantification of proteins in a sample is vital across life sciences, pharmaceutical research and clinical diagnostics, and a variety of equipment is available to scientists to simplify the workflow. Proteins of interest can be easily labeled and detected on light-based detection instruments. Immunoassay kits allow you to identify a specific protein of interest and protein detection beads or antibody microarrays allow you to identify multiple specific proteins at once. Protein interactions and enzyme activity can also be monitored with protein-protein interaction assays. Additionally, the biophysical characterization of proteins is made easy with biokinetic analyzers. Find the best protein detection and quantification products in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.Protein ExpressionProtein expression is the utilization of cell machinery for the synthesis of proteins and has become a critical tool in biotherapeutic, genomic, and proteomic research. Produce recombinant proteins with expression vectors in combination with a host cell suitable for high-level protein expression. For production of toxic proteins, consider cell-free expression vectors. Create and monitor post-translational modifications with protein modification kits. Find the best protein expression products in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.NeuroscienceNeuroscience research investigates the neurological mechanisms underlying behavior, neurodegenerative diseases, and other brain conditions. Learn about the innovative technologies for bioimaging, electrophysiology, cell culture, chromatography and other techniques used in this field.Protein InteractionsProtein interactions are essential for understanding cellular processes, as proteins work together to carry out biological functions. Studying protein interactions can provide insights into disease mechanisms, drug development, and cell signaling pathways. Explore the best tools for protein interaction research in our peer-reviewed product directory; compare products, check reviews, and get pricing directly from manufacturers.Cancer ResearchCancer research aims to understand the mechanisms of cancer development and progression to improve prevention, diagnosis, and treatment. From molecular biology to clinical trials, research spans a wide range of disciplines, including immunotherapy, targeted therapies, and drug discovery. Explore the best cancer research products in our peer-reviewed product directory; compare products, check reviews, and get pricing directly from manufacturers.Drug DiscoveryDrug discovery is the process of identifying potential new medications, involving stages such as target identification, compound screening, and preclinical development. It relies on cutting-edge technologies like high-throughput screening, artificial intelligence, and molecular modeling to accelerate the identification of drug candidates. Drug discovery plays a pivotal role in developing new therapies for diseases ranging from cancer to rare genetic disorders. Browse our peer-reviewed product directory to find the latest drug discovery technologies, compare options, check customer feedback, and get pricing directly from manufacturers.Drug DevelopmentDrug development refers to the process of bringing a new drug to market.Protein BiologyThe analysis of protein expression, identity and function is vital for many areas of life science research and drug discovery. Some of the most commonly used techniques in protein analysis include Western blotting, electrophoresis and mass spectrometry.
Targeting protein-protein interactions (PPIs): Identifying PPI inhibitors for novel therapeutics